cfMSC therapy for diabetes

Preclinical

cfMSC therapy for diabetes is one of 3 therapeutic programs targeting Type II Diabetes Mellitus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Type II Diabetes MellitusNot yet recruiting

Type II Diabetes MellitusPreclinical

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Type II Diabetes Mellitus

#DrugCompanyPhaseTrials

CX11

CCorxel Pharmaceuticals

Phase 2

1 2

Chronulac

SSolvay Pharmaceuticals

Preclinical

1 3

cfMSC therapy for diabetes

SShenzhen Geno-Immune Medical Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

PreclinicalNot yet recruiting

Type II Diabetes Mellitus

NCT07495956

Clinical

Trials by Indication[1]

Type II Diabetes Mellitus1 trial

Clonal Fetal Mesenchymal Stem Cell (cfMSC) Therapy for Type II Diabetes Mellitus

Not yet recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT07495956·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for cfMSC therapy for diabetes. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for cfMSC therapy for diabetes. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shenzhen Geno-Immune Medical Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShenzhen Geno-Immune Medical Institute

cfMSC therapy for diabetes

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Type II Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News